WINNIPEG, MANITOBA--(Marketwire - March 18, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, has announced that it enrolled the first patient in the phase II proof of concept clinical trial of DM-83.
